Biotech firm Dendreon Pharmaceuticals LLC in Seal Beach named Jason O’Neill its chief executive officer. He started June 1.
“My experience developing successful growth and market entry strategies is a timely addition to the company,” O’Neill said in a press release.
The appointment comes as Dendreon seeks to “expand access to the life-extending benefits of Provenge,” an FDA-approved immunotherapy that treats prostate cancer.
O’Neill most recently served as chief executive officer at Iridium Therapeutics, an early-stage pharmaceutical company developing improved therapies for breast cancer.
He also led Paris-based Sanofi’s oncology portfolio, which included Taxotere, the most widely prescribed chemotherapy for metastatic prostate cancer, for nearly 6 years and served as global therapeutic area head for immunology and ophthalmology at Roche.
Dendreon on May 17 said it would use a phased approach to bring its employees back to work and protect its ability to supply Provenge amid the pandemic.